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CITRULLINATION OF THE MATRIX: A POTENTIAL LINK TO AGE RELATED 
CHANGES IN BONE TISSUE 
SAINIKHIL SONTHA 
ABSTRACT 
 There is a strong correlation between aging and risk of fractures that is 
independent of changes in bone quantity. Although the underlying processes that 
dysregulate the structural health and integrity of bone tissue without affecting 
bone-quantity with aging are unknown, one hypothesis is that changes affecting 
extra-cellular components of bone, particularly components of the mineralized 
matrix, may contribute to the decline in bone quality with aging. Citrullination is a 
post-translational modification where a peptidyl arginine is enzymatically modified 
to a peptidyl Citrulline by enzymes knowns as peptidyl arginine deiminases 
(PADs). Increased citrullination of proteins is associated with altered protein 
function and a loss of structural stability. We propose that citrullination could 
have negative effects on the structural integrity of bone matrix proteins by 
inducing a loss of proteostasis, a conditional loss of protein homeostasis. To 
address this, we examined whether the levels of citrullinated bone matrix proteins 
differs between young and old mice. Our results show that there is a profound 
increase in citrullination of extractable bone matrix with ageing. To assess if 
changes in citrullination contribute to bone mass and/or mechanical strength, we 
utilized an existing murine model in which citrullination is increased. Mice 
deficient in Protein Tyrosine Phosphatase Nonreceptor 22 (PTPN22), an inhibitor 
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of PAD4, and thus of citrullination, have been shown to have increased histone 
H3 citrullination in macrophages derived from Ptpn22-/- mice compared to WT 
controls. We assessed several properties of bone in both young and aged 
Ptpn22-/- animals. In young mice, deficiency in PTPN22 leads to an increase in 
bone matrix citrullination. However, we did not find a link between increased 
citrullination and bone loss, as measured by formation of bone resorbing 
osteoclasts. Further, no difference in bone mass or structural parameters was 
seen in either young or old Ptpn22-/- mice compared to wild-type littermates. 
Interestingly, there was also no clear relationship between degree of citrullinated 
bone matrix and genotype in older mice, possibly due to overall increases in 
bone matrix citrullination with aging. However, as it is clear that bone matrix 
citrullination increases with age and that this citrullination in younger mice can be 
modulated by PTPN22 deficiency, we plan to use Ptpn22-/- mice as a model to 
learn more about the effects of increased citrullination on mechanical strength 
and bone matrix properties, therefore unearthing new insights into the role of 
post-translational modification in the function of bone matrix proteins.  
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INTRODUCTION 
 
The structural integrity of bone and resistance to fracture is derived from 
the combined properties of bone mass, bone geometry, and tissue material 
properties that contribute to bone quality. 
It has been observed that one in five women that were prone to hip 
fracture died as a direct result of the fracture.1 Moreover, amongst those that 
survived there was a severe decline in the ability to functionally attend to daily 
activities for a period as late as one year post-fracture. It has further been 
observed that bone-quantity was a not a good predictor of fracture risk. While 
bone quantity clearly declines with aging, age predicts risk of fracture 
independent of bone quantity suggesting that bone quality decreases inversely 
with age. However, the underlying mechanisms that perpetuate age-related 
decreases in bone quality are not well understood. There is a growing body of 
work that suggests a correlation between bone-quality and post-translational 
modification of bone matrix.  
Bone tissue, a vital component of the skeletal system, is essential in 
providing a framework of structural support. It protects internal organs from 
mechanical stressors and moreover, in concordance with the muscular system, it 
aids in movement and locomotion. Another vital attribute of bone is to act as a 
store of mineral ions like phosphate and calcium to assist the endocrine system 
in maintaining the blood and sera concentrations of these ions within a narrow 
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physiological range. A third vital function is to serve as the site of erythropoiesis 
and contain a niche to maintain hematopoietic stem cells. 2 The homeostasis of 
bone is governed by a profound balance between osteoblast mediated bone 
formation and osteoclast mediated bone resorption. The tipping of this balance in 
either direction can lead to serious issues that can compromise bone health and 
structure. 
Cellular and extracellular constituents of bone: 
Bone is composed primarily of extracellular protein matrix comprised of 
collagen 1 fibers and associated proteins including proteoglycans, 
glycosaminoglycans and multi-adhesive glycoproteins. This matrix is mineralized 
by the deposition of calcium phosphate in the form of hydroxyapatite crystals.3 
The particulars of bone extracellular matrix will be discussed in more detail in the 
section “Composition of bone matrix” below.  
The cellular components of bone comprise only a small portion of bone 
mass but are essential for maintaining bone structure. The main cell types in 
bone tissue are osteoblasts, osteocytes, and osteoclasts.  The formation of bone 
and its resorption is a dynamic process that is a summation of an equilibrium 
between the two individual processes. The main proponents of bone formation or 
osteogenesis are osteoblasts and, to a certain extent, osteocytes. Osteoblasts, a 
family of cells that are mesenchymal in origin, are essential in producing many 
organic components that form the structure of bone matrix including collagen 
fibers and proteoglycans prior to mineralization of bone.4 Osteoclasts actively 
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resorb and remodel bone tissue to fine-tune its structure and morphology. 
Osteocytes are cells that are localized in mineralized bone and play a major role 
in mechonosensation. For the purpose of this thesis, the contributions of 
osteobasts and osteoclasts towards maintaining bone homeostasis will be 
discussed in detail. Although osteocytes are major local orchestrators of bone 
functions and also function as endochrine cells in regulating phosphate transport, 
their functions are not directly relevant to the background of this project and 
hence will not be discussed in detail.  
The widely accepted model for the formation of bone tissue proposes that 
the process is kick-started via the formation of ossification centers. The flat 
bones of the skull, jaw and mandible are formed via a process known as 
intramembranous ossification wherein osteoblasts mediate matrix formation 
leading to subsequent ossification without the need for a cartilage precursor. 
However, in the case of long bones and other bones, there is a hyaline cartilage 
precursor that is first laid down as a structural framework by chondroblasts and 
chondrocytes via a process known as endochondral ossification. It is upon this 
cartilage framework that osteoblasts begin work to craft bone by laying down a 
range of complex proteins.5  
Osteoblasts – Bone Builders: 
 
 Osteoblasts can originate from either neural ectoderm, which contributes 
to the formation of round bones, or from paraxial mesoderm, which contributes to 
the formation of long bones. Both these populations arise from a common 
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precursor known as mesenchymal stem cells (MSCs).2 Activation of the runt-
related transcription factor 2 (RUNX-2) transcription factor in MSCs leads to the 
committed step towards the osteoblast lineage. In intramembranous ossification, 
osteoblasts form round-bones without the support of a cartilage precursor. The 
activation of the Sox9 transcription factor is essential for the differentiation of 
MSCs into an osteo-chondro progenitor that is essential for the formation of 
chondroblasts and perichondral cells that form a hyaline cartilage precursor that 
is replaced by bone in a process called endochondral ossification.6  
 Upon the formation of hyaline cartilage, chondrocytes are able to induce 
the differentiation of perichondral cells into osteoblasts via the activation of 
transcription factor Runx2 by paracrine signaling. In some cases, they are 
themselves able to cross-differentiate into osteoblasts to form the mineralized 
matrix precursor of long bones. In bone pathways, canonical wnt signaling leads 
to the stabilization of -catenin and activation of Runx2. It is this step that is 
thought to be necessary for osteoblastic morphology. The target genes of Runx2 
include osteopontin, osteocalcin, osteoprotegerin, Rankl, etc. 7 
 Upon differentiation, osteoblasts begin to secrete several proteins, 
including collagens that comprise the major extracellular constituent of bone 
ECM. The particulars of collagen synthesis will be explained in the section 
“Synthesis and assembly of tropocollagen I” Besides synthesizing and 
maintaining bone ECM, Osteoblasts are also involved in the mineralization of the 
organic matrix by secreting matrix vesicles. These are extracellular vesicles 
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found in an osteoid. The unmineralized matrix and they contain key enzymes like 
alkaline phosphatases, adenosine triphosphatases (ATPases) and inorganic 
pyrophosphatases combined with proteinases such as plasminogen activators. 
This essential contribution of osteoblasts is critical for the formation  of  seeding 
sites that enable hydroxyapatite crystal formation through localized enzymatic 
accumulation of calcium and phosphate.8  
Osteoclast: Bone Sculptors 
 Osteoclasts are the cell type that is responsible for bone remodeling and 
resorption. Osteoclasts are a unique type of multinucleated cells that arise as a 
result of a complex fusion of mononuclear monocyte precursors. Osteoclasts are 
structurally specialized to secrete acid and proteases to resorb bone. Hyper-
activation of osteoclasts is the consequence of many inflammatory diseases as 
well as autoimmune conditions that result in a net loss of bone quality and 
quantity. It is well established that osteoclast differentiation requires activation of 
a cell surface receptor, receptor activator of NFKB ligand (RANK) via the binding 
of its ligand – RANKL.9 RANKL is expressed by osteoblasts and osteocytes and 
induces osteoclast differentiation via a process known as osteoclastogenesis.11  
Osteoclasts are polarized cells that produced a number of degradative 
enzymes, ion channels, and receptors that help regulate their activity, including 
cathepsins, tartrate resistant acid phosphatase (TRAP), vacuolar proton ATPase, 
calcitonin receptors, and vitronectin receptors.4 Osteoclast polarization promotes 
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differing microenvironments on either of its poles. On the surface that is 
appositional to the bone resorption area, the osteoclast membrane forms a highly 
folded ruffled membrane that is teeming with H+ Atpases.9 This promotes a 
localized acidic pH of ~4 that is poised to demineralize the highly mineralized 
bone matrix. Upon demineralization, the organic components of the bone are 
subsequently degraded by lysosomal proteases - Cathepsin A, B, K. Both bone 
formation and resorption are constantly in balance with each other and occur 
continually and simultaneously at various parts of the skeletal system.11 
 Early studies have shown that osteoclastogenesis occurs in micro-
niches that are termed bone remodeling compartments. The process of bone-
remodeling can be simplified into four essential processes. First, bone-
remodeling is initiated by the recruitment and activation of osteoclast precursors. 
Thereafter, osteoclast differentiation occurs by cell fusion and maturation induced 
by the cytokine milieu that includes activation of Macrophage Colony Stimulating 
Factor (M-CSF) receptor and RANK by cell to cell interaction of these precursors 
with stromal/osteoblast cells that provide M-CSF and RANK ligand (RANKL). The 
third step is characterized by prominent bone formation by osteoblasts that is 
characterized by the formation of osteoids - areas rich in organic components of 
the bone matrix. This crucial step is responsible for the population of bone 
extracellular tissue and for the creation of a physical structural framework. The 
final step involves the mineralization of the osteoid. This entire process is under 
tight control and the dysregulation of either arms of the see-saw of bone 
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formation and bone resorption can lead to serious deleterious effects pertaining 
bone quality and bone health (Figure 1).12  
Figure 1: Bone Homeostasis. Adapted from Adapted from Kim, et al., Molecules, 2018.13 
The balance between bone resorption by osteoclasts and bone formation by osteoblasts is 
responsible for maintaining bone health and homeostasis. 
Composition of Bone Matrix 
The composition of the bone extra-cellular matrix (ECM) is an amalgam of 
highly hydrated macromolecules that are comprised of glycosaminoglycans 
(GAGs), proteoglycans, and multi-adhesive glycoproteins and calcium phosphate 
in the form of mineral crystals of hydroxy-apatite. Of the various proteins, the 
majority of the ECM is comprised primarily of fibers of type I collagen that are 
actively synthesized by Osteoblasts.7 The fundamental structural unit of type I 
collagen (tropocollagen) is a long (300-nm), thin (1.5-nm-diameter) protein that 
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consists of three coiled subunits: two α1(I) chains and one α2(I). Each chain 
contains a characteristic right-handed triple helix. The assembly of this fiber 
begins in the rough endoplasmic reticulum (RER) in a pathway similar to that of 
many secreted proteins. Although collagen is the most abundant protein of the 
ECM, there are many proteins that associate with collagen and perform a variety 
of functions. 
Non-collagenous proteins of the bone ECM comprise 10–15% of the total 
bone protein content. These proteins are multifunctional and have important roles 
in organizing the extracellular matrix, coordinating cell-matrix and mineral-matrix 
interactions, and regulating the mineralization process.14  
Synthesis and assembly of tropocollagen I 
 The complex pathway of tropocollagen assembly into collagen fibers 
traces its beginnings to the free ribosomes of osteoblasts. The first step is the 
translation of pre-procollagen mRNA. The ribosomes translate the mature mRNA 
beginning with a characteristic sequences of 22-26 peptide sequence known as 
the signal sequence.15 This ensures appropriate and efficient docking of the 
ribosome to the ER to for cotranslational -translocation of the pre-procollagen 
peptide. Once inside the ER, the signal sequence is cleaved off and the ensuing 
polypeptide chain is termed procollagen. 
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Intracellular posttranslational modifications: 
 Once translated, the polypeptides undergo a series of modifications that 
are essential to enable proper folding and assembly of the prospective collagen 
fibril. Most of the modifications begin to occur as the nascent polypeptide chain is 
being translated from the ribosome but continue to be modified until proper 
assembly of the alpha helix which in turn prevents further modifications to occur. 
Of these, the most significant modifications are the hydroxylation of the proline 
and lysine residues to yield hydroxyproline and hydroxylysine. This step is 
essential to confer additional hydroxyl groups that can participate in hydrogen 
bonding and confer better stability to the alpha helical fibril. The hydroxylysine 
groups are further glycosylated. 15 
 Thereafter, the individual helices begin to assume their secondary and 
tertiary structures, stabilizing with the aid of intramolecular disulfide bonds and 
hydrogen binding. They follow the normal route of secretion designated for 
extracellular proteins. The exact underlying mechanisms of procollagen secretion 
are still poorly understood. However, the presence of N- and C- terminal peptides 
prevent fibril self-assembly intracellularly. Once secreted, the alpha helices go 
through specific enzymatic cleavage of the N- and C-terminal propeptides by two 
major specific metalloproteinases – procollagen N-proteinase and procollagen C-
proteinase. They are enzymes that belong to the zinc-binding metalloproteinase 
family and are known to require Ca2+ for their activity. 3 
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Figure 2: Formation of extracellular matrix: collagen assembly and mineralization. Adapted 
from Wittkowske et al., Frontiers in Bioengineering and Biotechnology, 2016.16 1. 
Transcription of COL1A1 and COL1A2 occurs in the nuclear compartment. 2. Translation of 
COL1A1 and COL1A2 occurs in the RER. 3. Lysyl and prolyl residues on the polypeptide chains 
are hydroxylated and glycosylated. 4. Modified chains assemble. 5. Right-handed triple helix 
formation occurs. 6. Procollagen molecules are packed into secretory vesicles to prevent 
intracellular fibrillogenesis. 7. Procollagen molecules are secreted into the ECM. 8. N- and C- 
termini peptides are cleaved in the ECM by non-specific proteases. The molecule is termed 
tropocollagen 9. Fibrils form due to the cleavage of N- and C- termini peptides. 10. Fibrils 
aggregate to form fibers that are aided by cross-linking by lysyl oxidase. 
  
9.Tropocollagen formation 
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X-Linking with lysyl oxidase  
Once in the extracellular space, the aggregation of processed 
tropocollagen into fibrils with a characteristic D-periodicity proceeds with a key 
enzyme known as lysyl oxidase that is responsible for cross-linking specific lysyl 
and hydroxylysyl residues within and between separate collagen peptides. This 
key step is essential to confer collagen with the necessary structural and 
mechanical integrity to fulfill the demands of collagen as the underlying 
meshwork of the extracellular matrix.17  Further studies have elucidated the 
underlying mechanism of cross-linking to tease out the specific role of lysyl 
oxidase to reveal that the enzyme is solely responsible for the first step in the 
process whereby it generates lysyl and hydroxylysyl aldehydes via the process of 
oxidative deamination.18 Subsequently, variations of  di-, tri-, and tetrafunctional 
cross- linking amino acids form spontaneously by the intra- and intermolecular 
reactions of aldehydes generated by lysyl oxidase enabling efficient collagen 
polymerization. 
Lysyl oxidase is a cuproenzyme with a lysyl adduct of tyrosyl quinone at 
its active center that is essential for the transfer of electrons between oxygen and 
water in order to yield the essential aldehyde, ammonia and hydrogen peroxide 
as end products.19  
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Deamination and aldehyde formation: 
There are two major pathways that delineate the process of cross-link 
formation in collagen that is mediated by lysyl oxidase. In tissues including adult 
skin and eyes, the pathway predominantly makes use of lysine aldehydes. In 
bone, cartilage, ligament etc., the lysyl-hydroxyl pathway takes center stage.  
The first step, common to both pathways, involves the deamination of the 
ε-amino group in telopeptidyl lysine and hydroxylysine residues. This reaction 
yields their respective aldehydes, often referred to as allysine and 
hydroxyallysine.20  
Thereafter, in tissues such as bone, cartilage, and tendon, hydroxyallisine 
residues react spontaneously with lysines to form cross-links (figure 3).  
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Figure 3. Cross-linking of residues on Type-1 collagen. Adapted from Wang et al., Science, 
199619. Hydroxyallysine (I) interacts with a hydroxylysine residue to form the reducible cross-link 
dehydro-hydroxylysinohydroxynorleucine (II). Subsequently, II undergoes an Amadori 
rearrangement in vivo to form hydroxylysino-5-oxo-norleucine (III), which is resistant to heat and 
dilute acid. This can further be reduced to yield hydroxylysinonor- leucine (IV).  
 
Collagen Binding proteins (CBPs) 
Leucine-rich repeats (LRR) containing proteins 
 
 Many proteins containing leucine-rich repeats (LRRs) are found in a 
variety of organisms from mammals to bacteria. They contribute to a multitude of 
protein-protein interactions that range from signal transduction to the assembly 
and composition of the ECM. The main members of the ECM LRR 
glycoprotein/proteoglycan family have a small core protein domain flanked by 
cysteine rich clusters.21 Of the many ECM LRR proteins, the most widely 
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characterized proteins have a conserved LRR region containing about 24 amino 
acids and less conserved N- and C- termini.22   
 Decorin is well-known ECM LRR protein that binds to collagen type-I and 
has been shown to induce collagen fibrillogenesis in vitro.23 similarly, 
fibromodulin and lumican also have shown similar properties although they bind 
to a different site on the collagen type-I fibril than decorin. The significance of 
these ECM LRR proteins can be appreciated when considering their expression 
in a wide range of tissues including skin, bone, tendon, aorta, cartilage, placenta, 
heart, kidney, pancreas etc.23 Moreover, recent evidence suggests that these 
proteins may also be involved in regulation of cell growth, migration and 
adhesion. Specifically, decorin has been shown to interact with a range of 
proteins like fibronectin, thrombospondin, complement component C1q, 
epidermal growth factor receptor (EGFR), transforming growth factor- (TGF-) 
and binding to the latter two has shown to regulate cell growth by suppressing 
cell growth and reduction of fibrosis. 21 
 Studies have shown that collagen fibril assembly in the ECM is dependent 
on interactions with CBPs including decorin, fibromodulin as well as 
thrombospondin-2.22 
Cartilage associated matrix protein (COMP) 
Another protein that is crucial for collagen fibrillar assembly is a 
pentameric protein called cartilage associated matrix protein. Its role in 
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interacting with collagens and fibronectin is crucial for non-spurious folding of 
these large proteins. It has been shown to mediate the interaction of 
chondrocytes with the cartilage extracellular matrix through interaction with cell 
surface integrin receptors.24 Recent findings also suggest that it plays a role in 
the development of osteoarthritis that leads to loss  of bone.25 In light of such 
findings, it is becoming clear that the regulation of bone tissue is a complex 
process and the maintenance of bone homeostasis is not perhaps exclusive to 
the balance between the functions of osteoblasts and osteoclasts was previously 
thought. It is equally becoming important to understand the extra-cellular milieu. 
The most significant insight into the role of COMP is perhaps elucidated in 
the manifestation of a rare form of Osteogenesis Imperfecta (OI) that is 
characterized by brittle bones. Patients with OI suffer from spontaneous breaks 
in bone tissue often with no apparent cause or trauma. In 90% of cases of OI, 
there is a mutation in at least 1 of the collagen genes – COL1A1 and COL1A2 
that code for each of the alpha chains of type-1 collagen. However, in a rare form 
of OI that is designated OI type VIII, there is a mutation in COMP that manifests 
during embryonic bone formation leading to fractures in neonates. This speaks to 
the inherent role that the ECM and its proteins play in the stabilization of matrix 
components and in-turn of bone tissue.26  
Bone Mineralization 
 During the processes of matrix synthesis and calcification, osteoblasts 
become polarized cells that display characteristic features that signify active 
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protein synthesis and secretion. Matrix components are secreted at the cell 
surface in contact with existing bone matrix, producing a layer of unique 
collagen-rich material called osteoid between the osteoblast layer and the 
preexisting bone surface.  
Although the minutia concerning the process of matrix mineralization is not 
completely understood, the basis for it lies within the unique microenvironment 
that is created by the polarization of osteoblasts. Of the many non-collagen 
proteins secreted by osteoblasts, the protein that plays a key role in 
mineralization is the vitamin K-dependent polypeptide osteocalcin. Osteocalcin, 
along with various glycoproteins, binds Ca2+ ions that are exchangeable between 
vasculature and the ECM of bone thereby concentrating this mineral locally 
within the matrix.12 Osteoblasts also release membrane-enclosed matrix vesicles 
rich in alkaline phosphatase and other enzymes whose activity raises the local 
concentration of PO43- ions. These steps foster a microenvironment that is 
enriched with high localized concentrations of both these ions.11 Subsequently, 
matrix vesicles serve as foci for the formation of hydroxyapatite [Ca10(PO4)6(OH)2] 
crystals, the first visible step in calcification. Crystal growth proceeds from these 
initial foci in matrix vesicles to form spheroids, which gradually coalesce to form a 
network of apatite crystals. Type I collagen provides an additional mineralization 
mechanism by binding and orientating proteins, such as osteonectin, that also 
nucleate hydroxyapatite.4 These crystals grow rapidly by deposition of more 
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mineral and eventually produce a confluent mass of calcified material embedding 
the collagen fibers and proteoglycans.5  
Ageing 
Although it is a natural process that most organisms undergo, the exact 
biological definition nor the underlying mechanism of ageing is known. It is widely 
believed that aging is a process that is characterized by a progressive loss of 
integrity of the physiology, resulting in an impaired function and the eventual 
vulnerability towards death. The underlying physiological deterioration is the 
primary risk factor for major human pathologies, including cancer, diabetes, 
cardiovascular disorders, and neurodegenerative diseases.27 Aging research has 
experienced an unprecedented advance over recent years, particularly with the 
discovery that the rate of aging is controlled, at least to some extent, by genetic 
pathways and biochemical processes conserved in evolution. The time-dependent 
accumulation of cellular damage is widely considered to be the general cause of 
aging. In a landmark review, Lopin et al., characterized what they believed to be 
nine hallmarks of ageing inspired by the interactions of pathways that contribute to 
the accumulation of damage in cellular pathways in cancer.28 In this review some 
of the important processes described include genomic instability, epigenetic 
modifications, alterations to intercellular communication, cellular senescence and 
a progressive loss of protein homeostasis or proteostasis.  
 As far as loss of proteostasis is concerned, it has long been evident that 
some proteins or enzymes have fixed half-lives and cannot be replenished within 
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a lifetime. In fact, the natural loss of such proteins contributes to disease states. 
Elastin is one such protein that has a long half-life but is not readily replenished 
over the course of a lifetime.29 It has been evident that the destruction of elastin 
due to environmental triggers like cigarette smoke leads to emphysema.30  
Similarly, in diseases such as osteoarthritis (OA), it is becoming clear that 
an age-related dysregulation in articular cartilage homeostasis due to a 
dysregulation of ECM components leads to cartilage loss. It is perplexing that the 
risk of fracture increases with ageing irrespective of bone-quantity therefore 
strongly suggesting a mediatory role of the ECM in bone health and homeostasis.31 
Consequently, these findings beg a closer look at the ECM. 
Bone-matrix and aging 
 Although the development of skeletal tissue plateaus with age, bone is by 
no means a tissue that is suspended in static equilibrium. We have known for 
some time now that mineral deposition can change with age. We also know that 
the balance between bone resorption and deposition can also change with age 
and can change more for females than for males. Studies have also shown that a 
change in collagen cross-links can strongly correlate with bone structural 
integrity. Although changes in LO mediated enzymatic cross-links did not seem 
to be correlated with changes in bone micro-architecture, Boskey et al., found 
that an accumulation of non-enzymatic cross links formed by glycation- or 
oxidationinduced non-enzymatic processes, advanced glycation endproducts 
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(AGEs), such as glucosepane and pentosidine, tended to increase with age.32 
This finding prompted the authors to speculate that the rate of nonenzymatic 
cross-linking increases with age, while formation of mature enzymatic cross-links 
may decrease. Such changes could result in decreased strength and toughness 
of the bone and, ultimately, decreased resistance to crack propagation. 
 Another aspect of the ECM that was observed to be altered with age was 
both the amount and the distribution of ECM proteins as well as their PTMs. It 
was found overall protein production in bone-tissue decreased with age.33 Of the 
widely characterized PTMs, one PTM that plays a role in hair growth is 
citrullination. Citrullination of structural protein tricohyalin is important for hair 
structure as evidenced by the mutation in in an enzyme that citrullinates 
tricohyalin causing uncombable hair syndrome, a condition that is characterized 
by dry, frizzy hair that cannot be combed flat. This motivated us to look at 
whether ECM proteins in bone are citrullinated and if so whether age related 
changes in citrullination occur. 
Citrullination  
Citrullination is a key PTM that is essential for the proper folding of many 
proteins under physiological conditions. Since there is no tRNA for citrulline, it 
has to be a modification that is conferred unto the protein post-translationally. 
Under the control of enzymes known as peptidyl arginine deiminases (PAD), 
certain arginine residues are converted to citrulline residues in a process that is 
aptly termed citrullination. As early as 1939, citrullines were identified as residues 
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that may occur in proteins but their presence in the backbones of certain proteins 
was discovered later due, in part, to better amino acid sequencing techniques.34 
Besides their role in proper protein function and structure. PADs also modify 
peptidyl arginine residues on histones.  
Histones are essential proteins that contribute to the complex packing of 
DNA into condensed chromatin. Thus, alterations in the structural components of 
histones subsequently affect how they interact with DNA. This eventually plays a 
role in downstream processes like gene transcription. Histones, like other 
proteins, are susceptible to PTMs that regularly control relative levels of gene 
expression in the vicinity of the particular histone that is being modified. Some of 
the characteristic PTMs include acetylations, phosphorylations, methylation and 
ubiquitination that can either permit gene-transcription or inhibit it by varying the 
degree of chromatin-histone interaction. Recent studies have also exhibited the 
contribution of citrullination as a key PTM that can remodel chromatin.35 This 
modification is particularly interesting because overexpression of PAD and 
concurrent upregulation of enzyme activity has been observed in several 
diseases, including rheumatoid arthritis (RA), Alzheimer’s disease (AD), multiple 
sclerosis (MS), lupus, Parkinson’s disease, and cancer.35 
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The family of PADs 
 So far, in humans, five calcium dependent isozymes of PAD have been 
discovered that together comprise of the PAD family. Moreover, four of the five 
share roughly 50% sequence similarity.36 PADs are found in a myriad of cell and 
tissue types, summarized in the table below (Table 1.) 
Table 1. PAD isozymes and their localization in tissues. Adapted from Progress in the 
Chemistry of Organic Natural Products, 2017.37 
PAD Isozyme Tissue localization 
PAD1 Epidermis, uterus 
PAD2 skeletal muscle, brain, inflammatory cells, several cancer cell lines, 
and secretory glands 
PAD3 hair follicles and keratinocytes 
PAD4 granulocytes and several types of cancer 
PAD6 oocytes and embryos 
hile the PAD family of enzymes predominantly localizes in the cytosol 
predominantly, PAD4 is the only known isozyme that has, as of yet, been 
confirmed to also localize into the nuclear compartment due to the presence of a 
nuclear localization signal (NLS) in its N-terminal domain. Once inside the 
nucleus, PAD4 is primarily responsible for histone citrullination.  
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Figure 4. Localization of PAD enzymes in tissues. Adapted from Progress in the 
Chemistry of Organic Natural Products, 2017.37 
A growing body of work suggests that other substrates of citrullination by 
PADs include fibrinogen, fillagrin, and actin. It is pertinent that these proteins are 
often citrullinated in RA suggesting a possible contribution of this specific PTM 
towards pathogenicity. PAD4, the most widely characterized isozyme, has been 
shown to citrullinate a number of other proteins, including p300, ING4, RPS2, 
lamin C, nucleophosmin, and a host of other less well characterized substrates 
that were recently identified by screening protein arrays.35 
Untangling the role of PADs: PAD3 and hair follicles 
PAD enzymes are essential to many physiological processes. A well 
characterized model for PAD function under physiological conditions is PAD3. 
Experiments with sheep conducted by Rogers et al. show that PAD3 is co-
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expressed and co-localized with its natural substrate, trichohyalin, which is a 
major structural protein of inner root sheath cells of hair follicles.38 Trichohyalin is 
an important mediator of keratin filament aggregation. A key result of citrullination 
is the loss of arginine, a residue that is positively charged in physiological pH. 
Therefore, as a result of citrullination, trichohyalin opens its a-helical structure 
and renders it available for efficient cross-linking to keratin filaments by 
transglutaminase 3. This leads to the formation of a solid matrix that serves as a 
firm scaffold to guide the directional growth of the hair fiber. This was elucidated 
in a condition where the presence of an allelic variation of PAD3 resulted in a 
condition in humans known as uncombable hair syndrome. This was due in part 
to a mutation that suggested that the mutant  form of the enzyme was either not 
or only weakly active.39  
Figure 5. Effects of protein citrullination. Adapted from Vossenar et al., BioEssays, 2013.36 
Citrullination of arginine residues leads to a loss/gain of intermolecular interactions, loss of 
intramolecular interactions and subsequent protein unfolding, increase predisposition to 
proteolytic cleavage.  
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Mechanism of citrullination: 
Since the discovery of PADs, extensive research into their mechanism of 
action has yielded a model to better characterize the mechanism by which PADs 
citrullinate proteins. It is understood that PADs make use of a reverse protonation 
method where Cys645 functions as the active site nucleophile. Cys645 functions 
as a thiol group. The reaction follows as a two-step nucleophilic attack by the 
thiol group, followed by cleavage of carbon-nitrogen bonds to generate ammonia, 
with hydrolysis of the intermediate product resulting in peptidyl-L-citrulline. The 
other important residue in the active site, His471, functions as a general 
acid/base to facilitate the initial release of ammonia from the substrate 
guanidinium group and subsequently activating a water molecule to complete 
substrate hydrolysis.40 
 
Figure 6. Mechanism of citrullination. Adapted from Bicker et al., Biopolymers, 2013.35  
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Citrullination and bone loss 
Antibodies against citrullinated peptides drive bone loss 
 
 It has been discovered that anti-citrullinated protein antibodies (ACPA) are 
present in 50% of patients with early rheumatoid arthritis (RA). Assays that detect 
ACPA have very good diagnostic and prognostic characteristics for the disease.41 
Suzuki et al., hypothesized that the products of PAD enzymes in the synovium of 
RA patients may drive the development of autoantigens that are recognized by 
ACPA. To test this, they used cDNA libraries to immunoscreen a synoviocyte and 
discovered an autoantigen in Type I collagen. As type I collagen is the major 
component of the bone extracellular matrix, this suggests possible link between 
collagen, citrullination and bone loss.42  In support of this concept, Harre et al., 
found a strong and specific association between ACPA and serum markers for 
osteoclast-mediated bone resorption in RA patients.43  
Environmental irritants like cigarette smoke and silica dust risk pose 
significant factors for RA and, in particular, cigarette smoking is a risk factor for 
ACPA-positive RA. It has been suggested that the lung is an important site of 
protein citrullination and plays a role in the consequent generation of RA-related 
autoimmunity.44 In fact, cigarette smoke has been shown to increase PAD 
expression and protein citrullination in bronchoalveolar lavage cells of smokers 
without arthritis in comparison to non-smokers.45 Smoking is also a significant 
risk factor for bone loss and osteoporosis. Placing these studies in conjunction, it 
is likely that there is a link between ACPA and bone loss.  We hypothesized that 
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citrullination may be a potential mediator of age-related bone-loss or age related 
alteration in bone quality via modification of the properties of bone ECM proteins. 
In order to study the effects of increased and decreased citrullination on bone 
structure, we utilized existing mouse models that can either increase (Ptpn22-/-) 
or decrease (Pad2-/-) citrullination. 
PTPN-22: A negative modulator of PAD 
 
 It has been shown that PTPN-22, a receptor tyrosine phosphatase that is 
involved in signal transduction in T-cells, binds to and inhibits PAD4 thereby 
reducing levels of citrullination.46 It was further noted that polymorphisms in the 
PTPN-22 gene that cause a change in the primary structure of the protein by 
exchanging an arginine (R620) to a tryptophan (W620) inhibit the ability of PTPN-
22 to bind to PAD and thereby increase citrullination. Moreover, this key aspect 
of PTPN-22’s ability to modulate PAD and therefore modulate citrullination is 
independent of its phosphatase activity.  
 Using this information, we theorized that by using a knockout model of 
PTPN22, we could observe the effects of increase citrullination in a variety of 
tissues including bone.   
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Figure 7: Model of interaction between PTPN22 and PADs. PTPN22 binds to and inhibits the 
function of PAD thereby causing a net decrease in citrullination.  
PAD2 
 PAD2 is a PAD isozyme that is predominantly found in the colon, brain and bone-
marrow. Daamgard et al., studied the synovial fluid from RA patients and found that both 
PAD4 and PAD2 were capable of generating ACPA against citrullinated H3, alpha-
enolase and fibrinogen.47 In support of this finding, Nagai et al., also found that the 
mRNA expression of PAD2 and PAD4 was upregulated in rheumatoid arthritis bone 
marrow CD34+ cells independently of the systemic inflammation or treatment regimen.48  
 Using this information, we hypothesized that using a knockout model of PAD2 we 
would be able to observe the effects of systemic decrease in citrullination in tissues 
including bone.  
 28 
Specific Aims 
 Our findings that citrullination of bone matrix proteins increased with age, 
in combination with the literature suggesting a role for citrullination both in normal 
formation of structural proteins (as demonstrated by PAD3 deficiency), as well as 
in promoting bone loss in RA, let us to hypothesize that citrullination is a mediator 
of age-related changes in bone quantity and/or quality. The specific aim of this 
thesis was to determine whether increased citrullination of proteins in bone tissue 
results in increased bone resorption by osteoclasts and decreased bone quantity 
utilizing Ptpn22-/- mice in which PAD activity, and thus citrullination, is increased. 
We determined citrullination levels in total protein extracted from bone by utilizing 
two antibodies specific for citrullinated epitopes.  We then examined osteoclast 
differentiation and bone mass as assessed by μCT in Ptpn22-/- mice and their 
wild-type littermates. We examined both young and aged Ptpn22-/- mice as we 
hypothesized that any bone phenotype might be exacerbated with aging, due to 
increased citrullination of bone proteins seen with age.  
Additionally, we undertook several exploratory analyses of citrullination of 
bone extracellular matrix proteins. We determined whether deficiency in PAD2, 
one of the two PAD enzyme isoforms expressed in bone marrow, would alter 
levels of bone matrix protein citrullination.   
 29 
METHODS  
Mice 
CB6F1 mice were purchased from the NIA aging colony, maintained at 
Jackson Laboratory.  Ptpn22-/- and Pad2-/- were a kind gift of Dr. I-Cheng Ho. 
Mice were housed in microisolator cages with up to 5 mice per cage in specific 
pathogen-free animal facilities at Brigham and Women's Hospital vivarium under 
standard 12-hour light/12hour dark conditions Animals had access to standard 
mouse chow (PicoLab Mouse Diet 20, #5058, Lab- Diet) and water ad libitum. All 
studies were performed according to institutional and NIH guidelines for care and 
use of laboratory animals and were approved by the Brigham and Women's 
Hospital Institutional Animal Care and Use Committee. 
 
Micro-computed tomography (µCT) 
Imaging of femurs was performed with a Scanco Medical µCT 35 system 
with a voxel size of 7µm. Femurs were scanned in 70% ethanol with an X-ray 
intensity, an x-ray tube potential and an integration time of 0.145mA, 55kVp,and 
600ms respectively.  A region beginning approximately 0.3 mm proximal to the 
growth plate and extending 1.0 mm proximally was selected for trabecular bone 
analysis. A second region of 0.6 mm was selected at the center of the midshaft to 
represent cortical bone parameters.  An automatic as well as a manual 
contouring approach was utilized to determine the region of interest using a 
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threshold of 352.3 mgHA/cm3 for marrow/trabecular bone cut-off. Samples were 
encoded to blind the underlying genotype to ensure that analysis was performed 
blind to the genotype of the mouse sample. Bone parameters including bone 
volume fraction (BV/TV), trabecular number (Tb.N), trabecular thickness (Tb.Th), 
trabecular separation (Tb. Sp), trabecular bone mineral density (Tb.BMD), 
cortical thickness (Ct.Th) and cortical bone mineral density (Ct.BMD) were 
calculated with the software provided by the manufacturer in addition to the 
generation of the 3-dimensional images.   
In-Vitro Culture of Murine Osteoclasts 
Osteoclasts were cultured from hematopoetic progenitors found in bone 
marrow. Bone marrow cells were isolated from long bones by vigorously flushing 
the marrow with Hanks buffered salt solution (HBSS). The samples were pelleted 
by centrifugation at 200g for 5 minutes and cells were resuspended in complete 
α-MEM media (alpha-minimal essential media (GIBCO) supplemented with 
penicillin/streptomycin, 10% Fetal Bovine Serum (Hyclone)) containing 40ng/mL 
recombinant M-CSF (R&D) to drive myeloid cell expansion. Cells were plated 
onto suspension culture dishes (Corning Costar Ins) that stromal and lymphoid 
cells do not adhere to and expanded for three days. For osteoclast differentiation, 
expanded cells were lifted using non-enzymatic dissociation buffer (GIBCO). 
Cells were resuspended in osteoclast media (complete α-MEM containing 
5ng/mL RANKL (R&D) and 20ng/mL MCSF and plated at density of 2x104/cm2. 
Media was replaced on day 3 and 5. In order to assess osteoclast formation, 
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cultures were fixed in 4% paraformaldehyde for 10 minutes, washed, and stained 
for tartrate resistant acid phosphatase (TRAP) activity using standard methods.49 
The number of TRAP+ multinucleated cells was counted in triplicated assay for 
each animal and averaged to calculate the number of osteoclasts per 104  
precursors per animal. 
Protein Extraction 
Bones were extracted and stored on ice. Subsequently, the tops of the 
bones were cut off and bone marrows were flushed using a centrifuge run at 4 °C 
for 3 minutes at ~20000 rpm. Thereafter, the bones were placed in tubes with 
metal beads and cold tissue extraction reagent ii (Invitrogen) and blended using 
a Bullet Blender® (Next Advance) for 3 rounds of 5-minute-homogenization. The 
blended bone tissue was then pelleted using a centrifuge run at 4 °C for 2 
minutes at 8000 rpm. The supernatant was extracted and protein concentration 
was determined using BCA assay as per manufacturer’s protocol (Invitrogen). 
The lysates were stored at -30 °C. 
Western Blotting 
 Bone protein extracts were normalized to protein concentration, denatured 
with loading buffer and resolved on 4–15% gradient polyacrylamide gel (Bio-
Rad). Running conditions unless specified otherwise were a constant voltage of 
100V for 90-120 minutes using running buffer (glycine, tris, SDS). Gels were 
transferred to an activated PVDF membrane (Bio-Rad). Transfer conditions 
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unless specified otherwise were a constant current of 250 mAMPs for 120 
minutes using Icepack and cold transfer buffer (glycine, tris). PVDF membranes 
were blocked for 1hr at RT with 1% milk in 0.5% TBST. Incubations with primary 
antibodies were performed overnight at 4°C. Incubations with secondary 
antibodies were performed for 1 hr. at RT. Chemiluminescence was visualized 
using Luminata™ crescendo western hrp substrate (Sigma) and the Chemidoc 
™ gel imaging and documenting system (Bio-Rad). All primary antibodies were 
used as per manufacturer’s instructions Details of antibody usage are 
summarized in the table below (Table 2) 
Table 2. Summary of antibodies used 
1° Antibody 2° Antibody 
Name Manufacturer Dilution Name Manufacturer Dilution 
Actin Cell signaling 1:1000 Goat anti-rabbit  1:4000 
AMC Sigma 1:1000 Goat Anti-human IgG Sigma 1:2000 
F95 Sigma 1:500 Goat anti-mouse IgG Fisher 1:5000 
GAPDH Cell signaling 1:2000 Goat anti-rabbit  1:4000 
 
Statistical Analysis 
Graphpad Prism software was used for all statistical analysis. Unpaired, 2-tailed 
Student’s t tests or ANOVAs were used for all statistical comparisons. P values 
of less than 0.05 were considered statistically significant. 
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RESULTS 
 
Ageing and bone tissue: 
3.1.1: Effect of ageing on levels of citrullinated proteins in bone tissue of CB6F1 
mice  
 Western blot analysis was performed on protein extracted from femurs 
from 3, 9 and 12month old CB6F1 mice. Citrullinated protein epitopes were 
detected using the commercially available F-95 anti-citrullinated protein antibody.   
Four to five mice were analyzed per age group. In these wildtype mice, there was 
a marked increase in the levels of citrullinated protein levels in bone tissue of 
mice aged 24 months compared to 3 months when assayed with an F-95 
antibody (figure 8). There is also a suggestion of an increase in citrullinated 
protein to actin ratio in the 9-month cohort compared to the 3-month cohort. This 
is the first description of citrullination of bone protein that we are aware of.  
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Figure 8: Ageing and Citrullination. Western Blot showing levels of citrullination as detected by 
anti-citrullinated F95 antibody in CB6F1 mice aged between 3, 9, and 24 months of age. Actin is 
used as a housekeeping control. 
3.1.2: Age-associated increases in bone protein citrullination is also seen in 
C57BL/6 mice 
 To confirm the increase in bone protein citrullination seen in CB6F1 strain 
mice, the above experiment was repeated with C57BL/6 mice. It was critical to 
confirm that similar changes are seen in C57BL/6 mice, as that is the strain 
background of the Ptpn22-/- mice.  In this experiment, we compared the levels of 
citrullinated protein in bone tissue extracted from C57BL/6 mice aged 1 month 
old and 6 months old. Protein extracts from femoral bone were analyzed by 
Western blotting, with detection of citrullinated epitopes using both F95 antibody 
(Figure 9, left panel) and AMC antibody (Figure 9, right panel). AMC antibody is 
an alternative commercially available antibody used to detect citrullinated 
proteins. We observed that there was significant increase in levels of citrullinated 
proteins in bone extracts from mice aged 6 months of age compared to 1 month 
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of age when probed with both F-95 antibody as well as the AMC antibody (figure 
9). 
Figure 9: Citrullination in 1-month-old and 6-month-old mice. Western blot showing levels of 
citrullinated proteins in bone tissue of Ptpn22+/+ (C57BL/6) mice aged 1 and 6 months of age 
probed with anti-citrullinated F95 and AMC antibodies. 
PTPN22 and Bone 
3.2.1: Effects of PTPN22 deficiency on levels of citrullinated bone proteins  
 We next examined whether loss of PTPN22 function, which has been 
shown to increase PAD enzyme activity, led to increased bone citrullination.  
Protein extracts from femoral bone were analyzed by Western blotting, with 
detection of citrullinated epitopes using both F95 antibody (Figure 10, left panel) 
and AMC antibody (Figure 10, right panel). AMC. Our results showed that at 3mo 
of age Ptpn22-/- mice have increased levels of citrullination of extracted bone 
proteins compared to wild type mice. (figure 10).  
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Figure 10: PTPN22 and citrullination. Western blot showing levels of citrullinated peptides in 
bone tissue of 3-month-old mice in Ptpn22-/- and C57BL/6 Ptpn22+/+ controls. F95 anti 
citrullinated antibody panel on the left and AMC panel on the right.  
 
3.2.2: The effect of PTPN22 deficiency on osteoclast differentiation and function 
Since the deficiency of PTPN22 increased citrullinated peptide levels in 
bone tissue and increased citrullination and anti-citrullinated peptide antibodies in 
RA are associated with increased osteoclastic bone resorption, we asked if 
osteoclast differentiation was altered in Ptpn22-/- mice.  We assayed osteoclast 
differentiation from bone marrow precursors isolated from the long bones of 
Ptpn22-/- or wildtype mice and cultured them in vitro in the presence of MCSF 
and RANKL. After 5 days of differentiation, cultures were fixed and stained for 
TRAP activity. Multinucleated cells with TRAP activity were counted as 
osteoclasts. We initially examined both male and female mice at 8 weeks of age.  
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and found no observed increase in OC differentiation in Ptpn22-/- compared to 
Ptpn22+/+ controls (figure 11).  
Figure 11: PTPN22 and osteoclasts at 8 weeks of age. Osteoclast number in 8-week-old male 
and female Ptpn22+/+ and Ptpn22-/- non-littermates ascertained by TRAP staining. A. Number of 
multi-nucleated TRAP positive osteoclast cells per 2,500,000 cells. B. Microscopy panel of TRAP 
staining cells in Ptpn22+/+ and Ptpn22-/- male and female mice. 
As we had previously not examined littermate animals, nor tested 
osteoclast function, we repeated the above experiment using littermate controls 
and also asked if PTPN22 deficiency alters osteoclast function. We derived 
osteoclasts from bone marrow precursors by in vitro culture and determined both 
osteoclast number. In parallel, osteoclasts were cultured on calcium phosphate 
monolayers to assess osteoclast function as determined by resorption of the 
monolayer. Cultures were performed as above with the exception that bone 
marrow was isolated from 12-week-old mice. We again found no difference in 
osteoclast differentiation, nor were there obvious differences in osteoclast 
function in the Ptpn22-/- cultures. (figure 12).  
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Figure 12: PTPN22 and osteoclasts at 12 weeks of age. Osteoclast number in 12-week-old 
female Ptpn22+/+ and Ptpn22-/- littermates ascertained by TRAP staining. A. Number of multi-
nucleated TRAP positive osteoclast cells per 6,500,000 cells. B. Microscopy panel of TRAP 
staining cells in Ptpn22+/+ and Ptpn22-/- mice. 
 
PTPN22 and bone structure in 12-week-old mice 
3.3.1 The effect of PTPN22 deficiency on bone volume fraction BV/TV 
Although we did not detect a difference in osteoclast formation ex vivo, it 
is possible that the increased citrullination observed in Ptpn22-/- mice could 
cause differences in vivo that might be detected by changes in bone mass or 
trabecular structure as detected by µCT. Thus, we compared trabecular and 
cortical bone structural parameters in a small cohort of 12-week-old male and 
female Ptpn22-/- mice and wild-type littermate controls.  There was no difference 
in bone volume fraction (BV/TV), a measure of trabecular bone mass, observed 
in Ptpn22-/- mice compared to wildtype littermates in a cohort of 12-week-old 
mice in either males or females, although our conclusions must be seen as 
tentative given the small number of mice analyzed (Figure 13A). Future 
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directions include examination of a larger cohort of animals to more definitively 
address whether PTPN22 deficiency alters bone structure as assessed by uCT. 
In this cohort we also plan to test bone mechanical strength by 3-point bending.  
Figure 13: Trabecular bone quantity of male and female Ptpn22+/+ and Ptpn22-/- 
littermates.  A BV/TV of the distal femur in both male and female littermates aged 12 weeks of 
age. B 3-D model of trabecular bone of 12-week-old males and females. 
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3.3.2: The effect of PTPN22 deficiency on cortical bone 
Although no difference was seen in trabecular bone, to better understand 
effect of PTPN22 deficiency on bone structures, we also examined cortical 
parameters by uCT.  There was no significant difference in cortical thickness in 
Ptpn22-/- mice compared to Ptpn+/+ littermates in a cohort of 12-week-old mice, 
regardless of sex (Figure 14).  
Figure 14: Thickness of cortical bone of 12-week-old male and female Ptpn22+/+ and 
Ptpn22-/- mice.  
PTPN22 and bone structure in 12-month-old mice 
3.4.1 The effect of PTPN22 deficiency on bone quantity as assessed by μCT 
As we had seen an age-dependent increase in citrullination of bone 
proteins, we next looked at whether Ptpn22-/- mice might exhibit a bone 
phenotype with aging.  We bred a cohort of Ptpn22-/- and wild type (pooled +/+ 
and +/-) littermates and aged them to 12-months of age.  
Cortical Thickness 0.8/1/350
PTPN22 age 12 weeks, n=1 male, n=2 female
WT PTNP22 -/- WT PTNP22 -/-
0.00
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0.10
0.15
0.20
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Examining trabecular bone, we determined that there was no significant 
difference in trabecular bone parameters between Ptpn22+/? and Ptpn22-/- mice. 
We found no difference in BV/TV, Tissue mineral density, Tb.N, Tb.Th and TB.S 
(Figure 15). Representative images of trabecular bone are shown in figure 17. 
We confirmed that there was no overall dependence of genotype on trabecular 
bone quantity and that there was no observed sexual dimorphism in the effects of 
genotype on bone quantity. 
Similarly, examining cortical bone parameters, we determined that there 
wasn’t a significant difference in cortical parameters between Ptpn22+/? and 
Ptpn22-/- mice. Amongst the measured parameters, there was no difference in 
periosteal circumference, periosteal area, tissue mineral density, C.Th, and 
C.Po.(Figure16). Representative images of cortical bone are shown in figure 17.  
It was also evident from the cortical bone quantity parameters that there was no 
sexual dimorphism in the effects of genotype on cortical parameters 
Although it is clear from the bone quantity data that there was no 
significant difference in trabecular and cortical bone quantity in female Ptpn22+/+ 
and Ptpn22-/- littermates, we cannot exclude the possibility of a bone phenotype 
in males given the small number of males used in the study and the significant 
within-group variation. 
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Figure 15 Graphs of trabecular parameters in 12-month old control and PTPN22 deficient 
mice. Wild type mice are pooled Ptpn22+/+ and +/- and are denoted as +/? All trabecular 
parameters are graphed with each point representing one mouse. Significance was determined 
by one-way ANOVA. 
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Figure 16 Graphs of cortical parameters in 12-month old control and PTPN22 deficient 
mice. Wild type mice are pooled Ptpn22+/+ and +/- and are denoted as +/?. All cortical 
parameters are graphed with each point representing one mouse. Significance was determined 
by one-way ANOVA.  
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Figure 17: 3-D model of Cortical and Trabecular bone. 3-D reconstruction of trabecular and 
cortical bone of 12-month old control and PTPN22 deficient females. Bone quantity is as 
expected for aged female mice irrespective of genotype. 
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3.4.2 The effect of PTPN22 deficiency on levels of citrullinated proteins in bone 
tissue 
 We next examined the level of citrullination of protein extracted from the 
bones of 12-month-old control and PTPN22 deficient littermates to better 
correlate any bone quantity phenotypes with underlying levels of citrullinated 
peptides in bone. Using an anti-citrullinated peptide F-95 antibody, it was 
determined that there was no significant difference between levels of citrullinated 
peptides in controls compared to PTPN22 deficient littermates (figure 18). 
Figure 18: PTPN22 and citrullination in aging. Western Blot of citrullinated peptides in 12-
month-old control and PTPN22 deficient females probed with an anti-cit F95 antibody. GAPDH 
was used as a housekeeping control to ensure the loading of equal levels of proteins in each 
group. 
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 The same samples were also probed with an Anti-modified-citrulline 
(AMC) antibody that is more specific for citrullination. Echoing the results of the 
western blot probed with F95 antibody, in the AMC blot, it was also determined 
that there was no significant difference in levels of citrullinated proteins extracted 
from bone tissue of 12-month-old control and PTPN22 deficient females with 
GAPDH used as a housekeeping control. (Figure 19) 
 
 
Figure 19: Western Blot of citrullinated peptides in Bone Tissue. Anti-modified Citrulline 
antibody was used to detect citrullinated protein levels. GAPDH was used as a housekeeping 
control. 
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PAD2 and bone tissue 
3.5.1 The effect of PAD2 deficiency on levels of citrullinated proteins in bone 
tissue 
 
To assess the effects of PAD2 deficiency on bone protein citrullination, we 
extracted proteins from pooled femoral and tibial bone of Pad2-/- females aged 6 
weeks, 3 months and 12 months of age. Based off of the results of western blots, 
it was determined that a deficiency in PAD2 did not affect the levels of 
citrullinated proteins extracted from bone tissue in mice aged 1.5 and 12 months 
of age.  
 Probing with the anti-citrullinated F95 antibody, bands of size 75kD were 
resolved and the relative intensity of fluorescence was similar in both genotypes 
in both age groups (figure 20). The loading control actin revealed roughly 
equivalent loading between each group.  
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Figure 20: Western Blot of citrullinated peptides in bone tissue of control and PAD2 
deficient mice. The blot was probed with anti-cit F95 antibody to detect levels of citrullinated 
peptides. Actin was used as a housekeeping control to ensure the loading of equal levels of 
proteins in each group. 
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DISCUSSION 
 
 We found that citrullination of proteins extracted from bone, which consists 
of collagen type I and other matrix proteins, increases with age in mice of both 
the CB6F1 and C57BL/6 strain. We then aimed to determine whether 
citrullination of bone matrix proteins might contribute to regulating either bone 
mass or bone quality by assessing bone in mice deficient in PTNP22, a negative 
regulator of citrullination.   
   To assess citrullination of bone proteins, we used two antibodies that are 
widely used to characterize citrullinated peptides in western blots. The F95 anti-
citrulline antibody is non-specific to citrullination and also recognizes PTMs like 
carbamylation. The anti-modified citrullinated antibody relies on a modification of 
peptides with a strong acid solution to ensure visualization of citrullinated bands. 
Incubation with AMC typically yields bands of multiple sizes corresponding to a 
gamut of citrullinated peptides. An important caveat in interpreting age or 
genotype effects on citrullination is that throughout our studies we found 
substantial individual to individual variation in citrullination bone protein within 
any given group.  
We examined the levels of citrullinated peptides in extracts of bone from 
Ptpn22-/- and Ptpn22+/+ mice aged for 1 month and 6 months of age. In this 
experiment, we observed that there was a significant increase in levels of 
citrullinated peptides in bone tissue of Ptpn22-/- compared to that of Ptpn22+/+ 
mice. However, since only 1 pair of mice per age per genotype was used, we 
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decided to confirm the effects of PTPN22 deficiency in a second cohort of mice, 
an examining 2 mice per genotype at 3 months of age. We confirmed that a 
deficiency in PTPN22 indeed led to an increase in citrullination of bone tissue 
ascertained by both F95 and AMC antibodies.  
 Primed with this knowledge, we decided to probe if an increase in 
citrullination brought on by a deficiency in PTPN22 would lead to increased 
osteoclastogenesis. We did not find any effect of deficiency in PTPN22 on 
osteoclast formation or activity. We next asked if PTPN22 deficiency might affect 
quantitative bone morphometry, and assessed bones of 12-week old Ptpn22-/- 
and Ptpn22+/+ mice by μCT. We observed no significant difference in either 
cortical or trabecular parameters, with the caveat that a small sample size used 
for µCT could obscure small differences in bone structural parameters.  As 
citrullination of bone proteins appears to increase with age, we then examined 
the effect of PTPN22 deficiency on the bone phenotype of 12month old animals. 
We aged Ptpn22-/- and mice wild type for Ptpn22 (pooled +/+ and +/- littermates) 
for a period of 12 months and analyzed bone structure by µCT. Analysis of 
variety of trabecular and cortical parameters showed that there was no significant 
difference in bone structural and mineralization properties between Ptpn22-/- and 
Ptpn22+/+  mice in females. No difference was seen in males, either, with the 
caveat that the small sample size and high within-group variation might obscure 
true differences.  As we did not detect differences in bone morphometric data 
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between Ptpn22-/- and Ptpn22+/+ mice, and Ptpn22 is generally considered 
haplosufficient, we pooled Ptpn22-/- and Ptpn22+/+ for analysis.  
 To confirm that PTPN22 deficiency alters bone protein citrullination in 
older mice, as well as in younger mice, we examined bone protein citrullination in 
this cohort by Western blotting.  Interestingly, no difference in levels of 
citrullinated peptides in bone tissue of female Ptpn22-/- and Ptpn22+/+ mice was 
detected at 12 months. This could explain a lack of differences in bone 
morphometric data obtained using µCT in these mice. It could also suggest that 
at 12 months of age, the effect of age on bone citrullination may overtake any 
effect of genotype.  
 It was also interesting to note that a deficiency of PAD2, a PAD isozyme 
that is responsible for citrullination did not yield a decrease in bone protein 
citrullination at any age. This calls to question the efficacy of the Pad2-/- in 
regulating citrullination levels in bone tissue. However, due to sample size of n=1 
per age per genotype, it is not possible to make significant conclusions regarding 
the role of PAD2 in regulating bone protein citrullination from the results of SDS-
PAGE. 
 Our initial observation of an increase in bone matrix protein citrullination 
with aging, in combination with the literature about the effect of citrullination on 
structural protein function and bone resorption, led to much excitement and the 
hypothesis that citrullination might alter either bone resorption and thus bone 
quantity, or potentially alter bone quality by modification of matrix properties, 
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these hypotheses have proven more difficult to test than anticipated. In this 
thesis, we were only able to test whether alterations in citrullination result in 
increased bone resorption and decreased bone quantity. We found quite 
conclusively that a mutation leading to increased bone citrullination in young 
mice did not affect bone mass at 12 months of age. In a small cohort of mice, we 
also see no effect at 3 months of age, but need to repeat this evaluation on a 
larger cohort. Additionally, we have not yet had the opportunity to assess bone 
quality as measured by bone mechanical strength testing and other methods that 
evaluate the qualities of the bone matrix. Limitations of this project include the 
difficulty in reproducibly assessing citrullination of bone protein, the absence of 
genetic manipulations that can decrease bone citrullination, and the lack of 
treatments that can decrease bone citrullination, thus making it difficult to 
definitively test the hypothesis that citrullination impacts bone quantity or quality.  
 It is challenging to provide context to the results in terms of ageing 
because the field of studying citrullination as a physiological marker for disease is 
very new. Recent reviews have arrived at a consensus that increased 
citrullination levels are oft found in most if not all inflammatory conditions.50 In 
order to piece together the complex nature of aging and its manifestation in bone 
tissue, we hope to characterize the effects of PTPN22 deficiency in a new 
expanded cohort of Ptpn22 -/- and Ptpn22 +/+ mice. We aim to hone in on the 
bone phenotypes of a lack of PTPN22 in both older and younger mice to better 
understand age related changes to bone quality by examining bone mass and 
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strength. We also aim to characterize the proteins that are differentially 
citrullinated with an increase in age by extracting protein from femoral tissue of 
old and young mice by employing the techniques of mass spectrometry. We 
hope that this would provide specific information on the changes to ECM with 
ageing with respect to citrullination and also provide protein targets to better 
study the effects of citrullination. 
Some challenges that were associated with this project predominantly 
have to do with the very nature of bone tissue. Since we were interested in 
analyzing the PTMs of proteins present in the mineralized and inaccessible ECM 
of bone tissue, it was very difficult to reliably extract proteins from bones. To 
overcome this, we used a range of processes from detergents that solubilize 
proteins to mechanical disintegration of bone pieces in order to dislodge protein 
attached to bone by using metal beats. Although this process is routinely used to 
extract lysates from tissue samples, the efficiency of this workflow is greatly 
reduced when using bone tissue. More efficient methods need to be developed 
to optimize the extraction of such proteins for future experiments. 
 Another possible avenue of variation between initial findings could stem 
from the natural variation in citrullination of proteins between animals. It is difficult 
to accurately control for animal to animal variation of a process that may not 
normally occur in bone. Additionally, the crude protein extraction methods used 
to routinely extract proteins from bone tissue could also cause variations to both 
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the kind and quality of proteins that are extracted into the buffer from each 
individual bone sample.  
 It is also challenging to narrow strategies used to manipulate citrullination 
levels because it is not readily known if any PAD isozymes localize specifically in 
bone tissue and whether they normally citrullinate a specific subset of proteins in 
the bone ECM. In order to better equip future studies, we are in the process of 
analyzing proteins extracted from bone tissue of WT young and old mice using 
mass-spectrometry to characterize proteins that are repeatedly citrullinated in 
young and old mice.  
In order to better make conclusions regarding the complex relationship 
between PTMs of proteins in the ECM, citrullination, aging and bone health, it is 
more suitable to use models that can be controlled to reliably, significantly and 
consistently alter citrullination levels between mice. 
 Irrespective of the presence of such challenges, the collective efforts to 
understand this PTM that is so vehemently implicated in disease states could 
truly provide a link between the age-related decline in bone quantity and bone 
quality and pave the way for the creation of therapeutics that could help 
ameliorate bone loss and breakage in older populations and ultimately improve 
their quality of life. 
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